Record mula sa primary source
Decision-gradeComplete response letter
Nanalo ang Outlook Therapeutics sa FDR appeal; nakaplano ang muling pagsusumite ng BLA sa Hunyo 2026
FDA's Office of New Drugs overturned the December 2025 CRL, ruling that NORSE TWO plus confirmatory data establish substantial evidence of effectiveness for LYTENAVA in nAMD. The company will file a Class 1 resubmission in June 2026, triggering a 60-day PDUFA clock.
Mahahalagang fact
- Na-file
- May 26, 2026, 11:15 AM
- Kaganapan
- Complete response letter
- Direksyon
- Positibo
- Kumpanya
OTLKOutlook Therapeutics, Inc.- Asset
- bevacizumab-vikg
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Kalendaryo
- Desisyon ng FDA (PDUFA) · Hul 29, 2026 · Complete response letter
Sipi mula sa source
EX-99.1 2 tm2615583d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Company plans to resubmit BLA to the FDA in June 2026 ISELIN, N.J., May 26, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND). The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovasc
Higit pa tungkol sa asset na ito
Decision-grade
Hul 24, 2026
09:01 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
Hul 24, 2026
12:00 AM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 16, 2026
12:02 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
01:15 PM
OTLKOutlook Therapeutics, Inc.Materyal
Hun 1, 2026
12:46 PM
OTLKOutlook Therapeutics, Inc.Materyal
Abr 7, 2026
08:15 PM
OTLKOutlook Therapeutics, Inc.Decision-grade
Dis 19, 2025
01:30 PM
OTLKOutlook Therapeutics, Inc.